« Return to News | CROs/Service Providers

Particle Sciences expands cGMP capabilities with thin films

Friday, June 15, 2012 09:09 AM

Particle Sciences, a drug delivery CRO of Bethlehem, Penn., has added new thin-film coating capabilities for preparing polymer film-based drug products from liquid formulations, under cGMPs.

“Increasingly, we are seeing a demand for thin film-based products, particularly with respect to transdermal drug-eluting patch products, and rapidly-dissolving strips,” said Garry Gwozdz, director of formulation services, Particle Sciences. “While we have been working in this area for some time, the acquisition of semi-automated coating equipment will allow us to screen more formulation approaches, and get our clients into the clinic faster with a commercially representative film-based product."

Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others.

Gwozdz added, "Particle Sciences already had cGMP hot-melt film extrusion capability and now with the addition of coating and drying capabilities for liquid-based formulations, our clients have access to a complete array of viable and scalable film-manufacturing technologies."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.